An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 2, 2008, Pages 179-184

  Tehrani Doost, Mehdi ^a,b   Moallemi, Shirin ^a   Shahrivar, Zahra ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b INSTITUTE FOR COGNITIVE SCIENCE STUDIES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

ABDOMINAL PAIN; ADHD RATING SCALE; ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONNER'S PARENT RATING SCALE; CONSTIPATION; DECREASED APPETITE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FLUSHING; HUMAN; IRRITABILITY; MALE; MENTAL INSTABILITY; NAUSEA; OPEN STUDY; RATING SCALE; SADNESS; SIDE EFFECT; SLEEP DISORDER; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MORPHOLINES; PERSONALITY ASSESSMENT; TREATMENT OUTCOME;

EID: 42549102665     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0034     Document Type: Article

References (26)

1. th ed., Text Revision (DSM-IV-TR). Washington, (DC), American Psychiatric Association, 2000.
2. Anderson GM, Cohen DJ: Neurochemistry of Childhood Psychiatric Disorders. In: Child and Adolescent Psychiatry - A Comprehensive Textbook, 3rd ed. Edited by Lewis M. Lippincott Williams & Wilkins, 2002, pp 46-60.
3. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A: Non-stimulant medication in the treatment of ADHD. Eur Child Adolesc Psychiatry 13 (Suppl 1): I102-I116, 2004.
4. nd ed. New York, Guilford, 1998.
5. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784, 1989.
6. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J: A prospective 4 year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437-446, 1996.
7. Biederman J, Spencer T: Attention deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242, 1999.
8. Biederman J, Spencer T, Wilens T: Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 7:77-97, 2004.
9. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711, 2002.
10. DuPaul GJ. Power TJ, Ansatopolus AD, Reid R (eds.): ADHD Rating Scale-IV, Checklists, Norms, and Clinical Interpretation, New York, Guilford Press, 1998.
11. Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 16:443-460, 1995.
12. Hansen C, Weiss D, Last CG: ADHD boys in young adulthood: Psychosocial adjustment. J Am Acad Adolesc Psychiatry 38:165-171, 1999.
13. Keith Conners C: Conners' Rating Scales-Revised, Technical Manual. Multi-Health Systems Inc., 1997.
14. Kratochvil CJ, Heiligenstein JH, Dittmann R et al.: Atomoexetine and methylphenidate treatment in children with ADHD: A prospective randomized open-label trial. J Am Acad Child Adolesc Psychiatry 41:776-784, 2002.
15. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatricts 108:E83, 2001.
16. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: One-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
17. Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A: Reboxetine as an optional treatment for hyperkinetic conduct disorder: A prospective open-label trial. J Child Adolesc Psychopharmacol 15:259-269, 2005.
18. Otka JE, Mercadante MT, Scahill L, Leckman JF: Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder (letter to editor). J Child Adolesc Psychopharmacol 11: 203-204, 2001.
19. Pliszka SR, McCracken JT, Maas JW: Catecholamines in attention deficit hyperactivity disorder: Current perspectives. J Am Acad Child Adoles Psychiatry 35:264-272, 1996.
20. Pliszka SR: The neuropsychopharmacology of attention deficit/ hyperactivity disorder, Biol Psychiatry 57:1385-1390, 2005.
21. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P: Six-week open-label reboxetine treatment in children and adolescents with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44:428-433, 2005.
22. Spencer T, Biederman J, Wilens T, Harding M, O'Donnel D, Griffin S: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad child Adolesc Psychiatry 35:409-432, 1996.
23. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S: An open-label, dose ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251-265, 2001.
24. Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SV: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649-656, 2002a.
25. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Keith Conners C, Potter WZ: Results from 2 proof-of-concept, placebo controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder, J Clin Psychiatry 63:1140-1147, 2002b.
26. Valentini V, Frau R, Di Chiara G: Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital context: Differences with mianserin and clozapine. J Neurochem 88:917-927, 2004.